Neuroendocrine carcinomas (NECs) are epithelial neoplasms showing morphologic, immunophenotypic or ultrastructural evidence of neuroendocrine differentiation. The 2017 WHO Classification of Head and Neck Tumours classifies NECs into well, moderately and poorly differentiated NECs according to light microscopic features, mitotic rate and presence of tumour necrosis. In this study, we performed next generation sequencing (NGS) using a targeted 161 cancer gene panel on a poorly differentiated NEC of the nasal cavity. The tumour was composed of large cells arranged in poorly formed glands and solid nests. The mitotic count rate was 30/10 HPFs and p53 protein was strongly expressed in all tumour cells. NGS identified a missense mutation, c.764T > G (p.Ile255Ser) in the TP53 gene with an allele frequency of 85%. This mutation results in an isoleucine to serine substitution and a non-functional protein. No other mutations were identified. These results suggest that TP53 mutations may drive oncogenesis in poorly differentiated NECs of the head and neck.
Introduction
Neuroendocrine carcinomas (NECs) are malignant epithelial neoplasms showing morphologic, immunophenotypic or ultrastructural evidence of neuroendocrine differentiation. The 2017 WHO Classification of Head and Neck Tumours classifies NECs into well, moderately and poorly differentiated according to microscopic features, mitotic rate and tumour necrosis [1] . Well differentiated NECs have < 2 mitotic figures per 10 high-powered fields (HPFs) and no necrosis; moderately differentiated NECs have ≥ 2 and ≤ 10 mitotic figures per 10 HPFs and/or necrosis; and poorly differentiated NECs have > 10 mitotic figures per 10 HPFs with or without necrosis. The latter category includes small and large cell NECs, which are distinguished based on the cytologic features of the tumour cells. In general, well differentiated NECs are associated with good outcomes while poorly differentiated NECs are almost invariably associated with distant metastases and poor prognosis [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Moderately differentiated NECs are associated with highly variable clinical behavior, which suggests that this category may represent a heterogeneous group [6, 12] .
Our understanding of the clinical and biologic characteristics of NECs of the head and neck may be limited by our reliance on histologic features for the classification of these neoplasms. Evidence from other organ systems suggests that well and poorly differentiated neuroendocrine neoplasms harbor unique molecular signatures and may in fact be distinct biological entities [13] . Few studies have assessed the genetic landscape of neuroendocrine carcinoma in the head and neck so it is unclear if the evidence from other sites applies to the head and neck. In this study, we performed next generation sequencing (NGS) using a targeted 161 gene panel on a poorly differentiated NEC from the nasal cavity in order to investigate possible molecular contributions..
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Materials and Methods
Molecular Analysis
DNA and RNA were extracted from formalin fixed paraffin embedded (FFPE) tissue from a tumor resection with cellularity > 30%. Tumor regions were isolated by macrodissection from 10 to 15 unstained sections, and DNA and RNA extracted using a co-isolation method on a automated extractor (Maxwell FFPE kit, Promega, Madison, WI). RNA was converted to cDNA prior to use in NGS. Molecular analysis was performed using 20 ng DNA and 40 ng cDNA with the Onconmine™ Comprehensive Assay v3 (OCAv3; ThermoFisher, Waltham, MA) on the IonTorrent™ S5 XL platform (ThermoFisher). The OCAv3 panel includes regions of 161 driver genes, and parallel testing of DNA and RNA (cDNA), enables detection of single nucleotide variants (SNVs), small insertions and deletions, copy number variants (CNVs) and gene fusions in targeted gene regions. Analysis of molecular variants was performed using the Ion Reporter software, with filtering to remove variants below 5% variant allele frequency, low quality variants, known germline polymorphisms, and synonymous variants.
Case Report
The patient was 49-year-old female who presented with a 1-year history of nasal congestion, anosmia, 15-pound weight loss and intermittent epistaxis. The patient had a 30 pack-years history of smoking having quit 4 years before her initial presentation. There was no history of exposure to woodworking, leather or industrial solvents. Endoscopic examination showed a large left-sided nasal mass.
A computed tomography scan of the head and neck revealed a 5.3 × 3.0 × 2.5 cm mass occupying the posterior nasal cavity and spheno-ethmoidal recess with extension to the olfactory grooves and nasopharynx (Fig. 1a, b) . Imaging of the chest and abdomen did not reveal any evidence of distant metastases. The patient underwent debulking of the nasal mass for a tissue diagnosis at an outside institution. Post-biopsy imaging demonstrated residual tumour in the posterior nasal cavity and cribriform plate. The patient underwent neoadjuvant chemoradiation with two cycles of high-dose cisplatin and a radiation dose of 50 Gy followed by planned surgical resection. The tumour demonstrated a modest response to neoadjuvant therapy (Fig. 1c, d ) and underwent endoscopic endonasal resection of the residual tumour with negative margins.
Microscopically the tumor cells were arranged in poorly formed glands and solid nests (Fig. 2a) . The glands contained pale luminal mucin but no intracytoplasmic mucin. The tumour was composed of large cells with ample cytoplasm, finely dispersed chromatin and inconspicuous nucleoli (Fig. 2b) . The background demonstrated necrotic debris and hemorrhage. The mitotic rate was 30/10 highpower fields and abnormal forms were easily identified. Patchy involvement of surface epithelium by tumour cells was also identified. No residual tumor was identified on follow-up imaging (Fig. 1e, f) and at the time of this report, the patient has been disease free for 14 months.
Immunohistochemical stains showed that the tumor cells were diffusely positive for pan-keratin AE1/AE3 (Fig. 3a) , CK18, CK19, and synaptophysin (Fig. 3b) . There was focal expression of chromogranin (Fig. 3c), CD56 (Fig. 3d) , p63, and CD117. No staining was noted for CK7, CK20, CK5/6, CD5, CDX2, S100, glial fibrillary acidic protein (GFAP) or CD30. A stain for p53 showed diffuse and strong nuclear expression (Fig. 3e) . The proliferative index as measured by Ki-67 was approximately 70% (Fig. 3f) . A PAS stain did not reveal any intracytoplasmic mucin. A diagnosis of poorly differentiated NEC was made.
Next generation sequencing performed on representative sections from the tumour identified a TP53 mutation, c.764T > G (p.Ile255Ser; I255S) with a variant allele frequency of 85% (Fig. 4) . The mutation results in an isoleucine to serine substitution and a non-functional protein. The I255S mutation is found in exon 7 of TP53, within the DNA binding domain encoded by exons 5-8 [14] .
Discussion
In this study, a TP53 gene mutation I255S was identified using NSG in a poorly differentiated NEC of the nasal cavity. Our data is consistent with two previous reports, which each identified a TP53 gene mutation in NECs arising from the maxillary sinus and parotid gland, respectively, using polymerase chain amplification [10, 15] . Our report is different, however, in that, NGS is able to sequence hundreds of known cancer associated genes simultaneously, and this allowed us to more fully profile the genetic landscape of this NEC. Somewhat surprisingly, we found that out of the 161 targeted gene regions analyzed, the TP53 I255S was the only variant of potential clinical relevance after filtering to remove known polymorphisms and synonymous variants (see "Materials and Methods"). This result suggests that TP53 gene mutations may play a significant role in the oncogenesis and progression of NECs in the head and neck.
The TP53 gene is prototypical tumour suppressor and the most frequently mutated gene in human cancer [16] . Mutations in TP53 cause dysregulation in a variety of cellular processes including cell cycle arrest, apoptosis, senescence,
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DNA repair, and metabolism [17] . The TP53 gene contains 12 exons but the majority of clinically relevant mutations occur in exons 4 through 9. These exons are known to encode for amino acids that form the central DNA binding core domain [18] . Common mutations in this region result in a protein that is unable to bind DNA thereby preventing transcription of p53-regulated genes. The TP53 I255S mutation in this report results from a T to G missense mutation located on exon 7. According to the catalogue of somatic mutations in cancer (COSMIC), this point mutation has been previously described in 14 occurrences in a variety of cancers arising from the lung, endometrium, esophagus, breast, bone, brain, oral cavity, and bladder [19] . The I255S mutation has also been reported in ten occurrences as a somatic mutation in the IARC TP53 database (two occurrences thyroid, two mouth, and one each in corpus uteri, bladder, brain, ovary, breast, lung). Because the p53 protein functions as a tetramer, the presence of a non-functional protein effectively inhibits the activity of the remaining wild-type proteins [20] . The lack of p53 activity results in increased protein production through disinhibition of a negative-feedback loop. Ultimately, the protein accumulates A growing body of evidence suggests that mutations in TP53 are a hallmark of poorly differentiated neuroendocrine neoplasms independent of site of origin. As early as 1996, Brambilla and colleagues used immunohistochemistry to show to TP53 was overexpressed in neuroendocrine tumours in the lung [21] . Subsequent studies have shown that the TP53 gene is consistently mutated in both small and large cell NECs of pulmonary origin [22] [23] [24] . In the gastrointestinal tract, TP53 gene mutations have been described in NECs arising from the colorectum and pancreas [25, 26] . More recently, TP53 gene mutations have been described in small cell NEC of the prostate [27, 28] . There have been only two previous studies to describe a TP53 gene mutation in neuroendocrine carcinoma of the head and neck [10, 15] . Franchi and colleagues described a mixed large cell NEC and squamous cell carcinoma of the maxillary sinus and used PCR to show that only the neuroendocrine component harbored a mutation in TP53 [15] Similarly, Nagao and colleagues used PCR to identify a TP53 mutation in a poorly differentiated neuroendocrine carcinoma of the parotid gland [10] .
The near ubiquity of TP53 mutations in poorly differentiated NECs is consistent with the concept that loss of p53 protein expression is an early event and a driver of oncogenesis in this tumour type. Indeed, in patients with small cell NECs of the lung, the same TP53 mutations have been detected in tumour cells and the adjacent morphologically normal bronchial epithelium [29] . Moreover, in lung, pancreatic, and prostate models of small cell NECs, knocking down the expression of p53 protein has been shown to induce the development of tumours that look and behave like their clinical counterpart [27, 30, 31] . These results are consistent with the notion that p53 acts as a 'defender' of genomic integrity and that loss of functional p53 results in genomic instability and the accumulation of other driver mutations which drive tumour progression. Functional p53, however, also acts directly to activate pathways that limit cell growth and the early loss of p53 protein would help explain the hyperproliferative state that both defines and characterizes high-grade NECs [32] .
The current WHO classification of head and neck neuroendocrine carcinoma was modeled after the system used for pulmonary NECs in that it relies primarily on the appearance of the tumor and mitotic rate of the tumour to establish a diagnosis and grade [33] . This classification system suggests that all three grades exist on a continuum, which is reflected in the mitotic rate. Recent genetic studies, however, suggest instead that neuroendocrine neoplasms are best dichotomized into "well differentiated" and "poorly differentiated" malignancies based on unique molecular alterations. Well differentiated neuroendocrine tumors in the lung and gastrointestinal tract (carcinoid and atypical carcinoid) display lower somatic mutation rates (< 1 per million base pairs) and frequently demonstrate inactivation of genes affecting histone methylation (MEN1) by multiple mechanisms and SWI/SNF complex subunit mutations [34] [35] [36] [37] [38] . In contrast, "poorly differentiated" neoplasms display a high rate of somatic mutations and the vast majority harbor mutations in both RB and TP53 [22] . Our results provide additional evidence that TP53 mutations may play a central role in the development and progression of poorly differentiated NECs in the head and neck. 
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